Table 1. Germline mutations and clinical characteristics of patients with PPGL at six university hospitals.
Cluster | Gene | No. case | Sex | Age at diagnosis (yrs) | Family history | Clinical diagnosis | Tumorlocation | Tumor size(max, cm) | Multiple tumors | Metastasis | Recurrence | Biochemical status | Othertumors | cDNA change | Amino acid change | ACMG interpretation | Consequence | ClinVar accession |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cluster 1. Pseudohypoxia (TCA cycle-related) | SDHD | 1 | F | 44 | Yes | PCC/PGL | Rt adrenal, carotid body | 2.0 | Mu | No | Yes | Nor | NM_003002.3(SDHD):c.119delT | p.Ile40ThrfsTer46 | P | Frameshift | Not reported | |
Cluster 1. Pseudohypoxia (VHL/EPAS-1-related) | VHL | 2 | M | 16 | No | PCC | Both adrenal | 4.0 | Mu | No | No | Nor | NM_000551.3(VHL):c.208G>A | p.Glu70Lys | P | Missense | VCV000043598.16 | |
VHL | 3 | F | 49 | No | PGL | Retroperitoneum | 3.5 | S | No | No | Nor | Lymphoma | NM_000551.3(VHL):c.242C>T | p.Pro81Leu | LP | Missense | VCV000036899.24 | |
VHL | 4 | F | 55 | No | PCC | Lt adrenal | 7.5 | S | No | No | Nor | NM_000551.3(VHL):c.499C>T | p.Arg167Trp | P | Missense | VCV000002218.31 | ||
VHL | 5 | M | 70 | Yes | PCC | Lt adrenal | 2.6 | Mu | Yes (bladder) | No | Nor | NM_000551.3(VHL):c.640T>A | p.*214Argext*14 | LP | Stop lost | VCV000801933.6 | ||
Cluster 2. Kinase signaling | NF1 | 6 | M | 35 | No | PCC | Rt adrenal | 4.5 | S | No | No | Nor | NF1 | NM_001042492.2(NF1):c.6596del | p.Leu2199Ter | P | Nonsense | Not reported |
NF1 | 7 | F | 56 | No | PCC | Lt adrenal | 1.6 | S | No | No | Nor | NF1 | NM_001042492.2(NF1):c.1748A>G | p.Lys583Arg | P | Missense | VCV000068306.21 | |
NF1 | 8 | M | 66 | No | PCC | Rt adrenal | 4.3 | S | No | No | Adr/Nor | NF1 | NM_001042492.2(NF1):c.4800dup | p.Ala1601SerfsTer21 | P | Frameshift | Not reported | |
NF1 | 9 | M | 40 | No | PCC | Lt adrenal | 6.0 | S | No | Yes | Adr/Nor | NF1 | NM_001042492.2(NF1):c.7869+1G>A | p? | P | Splice donor | VCV000480091.8 | |
RET | 10 | F | 64 | Yes | PCC | Both adrenal | 4.6 | Mu | No | No | Adr/Nor | NM_020975.4(RET):c.1891G>T | p.Asp631Tyr | P | Missense | VCV000024914.9 | ||
RET | 11 | F | 41 | No | PCC | Lt adrenal | 6.0 | S | No | Yes | Adr/Nor | MTC | NM_020975.4(RET):c.1902C>G | p.Cys634Trp | P | Missense | VCV000013918.19 | |
RET | 12 | F | 52 | No | PCC | Lt adrenal | 6.5 | S | No | No | Adr/Nor | MTC | NM_020975.4(RET):c.1902C>G | p.Cys634Trp | P | Missense | VCV000013918.19 | |
RET | 13 | F | 54 | Yes | PCC | Rt adrenal | 2.8 | S | No | No | Adr/Nor | MTC | NM_020975.4(RET):c.1902C>G | p.Cys634Trp | P | Missense | VCV000013918.19 |
Abbreviations: PPGL, pheochromocytoma and paraganglioma; F, female; M, male; PCC, pheochromocytoma; PGL, paraganglioma; Rt, right; Lt, left; S, single; Mu, multiple; Nor, noradrenergic; Adr, adrenergic; NF1, neurofibromatosis type 1; MTC, medullary thyroid carcinoma; P, pathogenic; LP, likely pathogenic